Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The main objective of the study is to show that the combination of imatinib mesylate (GLIVEC) and hydroxyurea is superior to hydroxyurea alone in prolonging progression free survival (PFS) of patients with GBM according to Macdonald-criteria.
Critère d'inclusion
- Glioblastoma multiforme/astrocytoma WHO grade IV, with progression on temozolomide containing regimen